Get started

Biotech

This looks...Familiar on ATOSThis is a very interesting level for ATOS right now. The last two times before this most recent instance the stock failed to break through and hold this level. It was able to do that briefly this year but unsustainable. After consolidating this last time around, what's the catalyst to actually spark a firm move? I think a lot will come down to the next steps for AT-301 to be honest: "Recently ATOS has received phase 2 initiation approval from the Swedish Medical Product Agency for its oral Endoxifen. This drug targets mammographic breast density (MBD), to reduce and eradicate potential tumors. MBD affects millions worldwide and can reduce the effectiveness of mammograms...Doctors around the world depend on mammogram studies to detect cancer through breast density. With a drug such as Endoxifen, it would increase the ability for earlier diagnosis, which in turn could reduce breast cancer incidence... This is a large breakthrough for the company and considering the incidence of breast cancer around the world, Endoxifen could be a big deal moving forward. Investors should stay up to date with any news regarding this compound, as it is Atossa’s flagship product. However, it does have a sizable pipeline that includes a Covid-19 nasal spray treatment known as AT-301." Quote Source: 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
NASDAQ:ATOS
by PennyStocks101
$MBRX Moleculin biotech $MBRX seems to have grit for sellThe Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data far above the expectations of analysts. Recently a reverse split of the stock has also been carried out that reduces the number of titles in circulation. In fact, today the Miracle Viewer indicator that analyzes the graph in search of interests in the market of large players shows an increase in LONG positions by the institutions so you could implement an upward price action. Analyzing the chart, the title seems to have some obstacles along the way but if the interests from the big will remain high will probably be surpassed with limited retracements, according to the signal of Marketmiracle the stock could go even further pushing at the price of 15,50 USD but I would not want in my graphical analysis to exceed the level I indicate as target as it is already a remarkable increment and during the path the title could lose strength. I will try to free cash and enter the stock also because at the moment the balance seems to be shifting a lot on pharmaceuticals and biotech companies so personally I think this is a good opportunity. ( see related other ideas on other biotech and pharma titles ) We will see in the next hours and days if the forecast of Marketmiracle will prove effective. This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:MBRXLong
by MarketMiracleAdvisor
2
$CAPR Target 7.61 for 42.51% $CAPR Target 7.61 for 42.51% Or next add level is at 3.07 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:CAPRLong
by SPYder_QQQueen_Trading
ENTX - Entera Bio Ltd on huge run - possible double againI bought this one several days ago and there is still a huge amount of upside. If it can get through the $4.30 and $4.80 resistance a double is a real deal. They have had solid revenues the last 2 Q and are based in Isreal. They have partnered in a project with Amgen and have been around I think since 2003. The Timeframes tell the story and the flow of the chart and long build up shows possible huge rewards near term. I am long for this company, but relatively short for this run...I think by next week we will be above $5 or $5.50.
NASDAQ:ENTXShort
by sid72
2
ONTX Onconova Therapeutics good results = good growthThere’s no reason in the world that a biopharmaceutical company like $ONTX that operates cancer research and has a very good quarterly should be stationary at the same price, rather lower than the time at which the quarterly report was submitted, which was excellent and above the expectations of the analyses. After a vertical takeoff he retracted his full price going, at present, to position himself about a 15% below. In addition, there has been a reverse split of stocks that reduces the number of shares outstanding, so the value of each individual share should increase significantly. The advisor Marketmiracle has in fact emitted a signal LONG on the Stock to the price of 6,64 usd with a target of 622 usd that is a vertical takeoff of 9268% identifying a massive entry of capitals and of interest LONG on the Stock from some great investor. Let’s just stay grounded and figure it out on the graph. The graph tells us that surely the title has the ability to climb without virtually obstacles to the resistance indicated, we see them further signs and we will reason whether the great climb should continue or not. A greater interest in biotechs and pharmaceuticals that for some time had been put aside gives us more reason to believe that the increase in price can actually take place ( see related ideas ) This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
OLong
by MarketMiracleAdvisor
7
APRE MASSIVE MOVE COMING JULY 16 CALL OPTIONSFirst, this stock is just beaten down in no way shape or form should it be at this price. 30% shorted really the only reason. Beat EPS decent ER nothing unordinary for a Bio stock. This is the definition of primed and ready to go. Extremely obvious with the candle build up at the bottom of the pattern. Easily a $5 target. Call options July 16th 7.50 call. Yes it seems weird since it's not a "liquid option" but is traded and will gain IV and price movement which is how you make the real profits. Even buying the stock it clearly has $5-$7 written all over it let alone a MASSIVE gap to fill.
NASDAQ:APRELong
by DigitalData
4
I imagine this... probably ... and it’s just the beginning.According to the indicator at the base of the advisor Marketmiracle the CLVS stock is accumulating capitals and is ready for an explosion. Clovis Oncology is one of the best-selling low-cost titles but produces a drug capable of improving the lives of cancer patients worldwide. Clearly the money devoted to biotech and pharmaceutical companies during the covid period was directed to vaccine manufacturers but now, that the clouds are clearing up and the covid danger seems to have drifted away, it seems to be heading back to what are the possible cures for the diseases of the century, namely cancer, This is also demonstrated by the recent rise in prices of $AHT, which is a cancer care company ( see related idea) I imagine a movement of the title as the one indicated in the graph, but I have the feeling that it will only be the beginning, the company a few years ago priced much but much more and its trails are successful as demonstrated by the recent results. Investing in a society like this is also a way to help medicine and the entire human race.. I did a search on the fundamental analysis sites that I use as a reference and it seems according to their analysts that the current price of Clovis Oncology is absolutely below the right value, which is given around 50 USD i.imgur.com I certainly put a chip on Clovis ... I think it’s a great opportunity. Scrolling at the bottom of this page you will find the advisor Market Miracle who gave a few days ago the input signal on $CLVS.
CLong
by MarketMiracleAdvisor
5
Short Squeeze - CMMBIdea for Chemomab Therapeutics Ltd.: - 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk. - Bottom of Risk Range: - S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io - Cantor Fitzgerald assigned overweight rating on CMMB and raised price target to $45. www.marketbeat.com - Good short squeeze material. - Non Optionable. Bought the shares $16.69 Expect share dilution $40-$50 GLHF - DPT
NASDAQ:CMMBLong
by UnknownUnicorn1043646
3
High Traffic Resistance & Upcoming CatalystThis week will be a potentially big one (in either direction for AGEN imo and it will come down to the data to tell which way the stock breaks...or breaks down. This week, AGEN stock could be on the list of penny stocks to watch. Two posters will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting from June 4 – 8, 2021.The focus will likely be on the specifics of the trial and its design. “We are encouraged by the differentiated qualities of our anti-PD-1 balstilimab both in the clinic and in preclinical…Our novel CD137, AGEN2373, has been well-tolerated in this dose-escalation trial, and we look forward to advancing it into combinations for potential benefit to patients,” said Steven O’Day, MD, Chief Medical Officer at Agenus, in a PR last week. Quote Source: Hot Penny Stocks To Buy On Robinhood With Upcoming Events This Week
NASDAQ:AGEN
by PennyStocks101
Humanigen $HGEN is ready for a breakoutThese past weeks we saw a lot of action regarding $HGEN - not that much pricewise, but more on a fundamental basis like the long awaited news about the date for the Emergency-Use-Authorization (EUA), identified as a key driver for demand and price action. Humanigen intends to request the EUA by June 2021. Looking at the chart, the price did not react as much to the news, most likely because of anticipation, whether they will receive the EUA or not (I assume they will). Humanigen has done a great job fulfilling the prerequisites (published Phase 3 data looks promising) and they recently had a meeting with the FDA to clarify the scope (www.biospace.com). Several rating companies have set the target at 40$, but looking at the chart and institutional interest there is clearly a bit more upwards potential than that. 30$ has been reached previously and with Blackrock increasing their position, as well as HGEN being the 5th largest holding in the XBI ETF a target of 60$, 86$ and 102$ is more likely. The big companies have done a great job in increasing their position without moving the stock's price too much. Right now we have a tight trading range and 20$ is working as a light resistance. A shakeout also occured yesterday and it is possible that more might follow. These are quite normal, as big companies try to improve their position. -This is no financial advice- For transparency: I am invested in $HGEN with 1/10 of my account size. I always keep buffer cash and never go all in!
HLong
by RedFoxTrading
Added & updated $NXGN Target 20.85 for 17.60% $NXGN Target 20.85 for 17.60% Or next add level is at 15.11 I added here and updated target... target is a little higher than before. Earnings were fine... — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NLong
by SPYder_QQQueen_Trading
NOVN Swing trade or long?Our ABML Play seems to be working out so far. Here is another Gem that could work our similar. I love cheap stocks. NOVN is a clinical development-stage biotechnology company, which focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Checking Wallstreetzen, it appears to be backed by all the big boys like Vanguard, Blackrock, Renaissance etc... The company is developing a treatment for Molluscum Contagiosum, soon to be the only one FDA approved for Molluscum treatment if everything goes well. The readout for their B206 trial in June is expected to arrive with positive results from the data. Entry : $1.45 TP : $3 SL : $1 Let's see how this plays out. (Disclaimer, not financial advice) NASDAQ:NOVN
NLong
by jackohgorman
3
$OBLN Target 6.65 for 43.32% $OBLN Target 6.65 for 43.32% Or next add level is at 2.63 This one was fun today... still quite a ways to target but heading that way... — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
OLong
by SPYder_QQQueen_Trading
5
Ultimovacs ASCO 2021 60% ORR 30% CR #cancervaccineUltimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data • UV1/pembrolizumab results in 30% complete responses plus 30% partial responses • Good safety and tolerability profile supports use of UV1 in combination treatments • Data to be presented at ASCO and abstract to be discussed in webcast on May 20, 2021 Oslo, 19 May 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients have been observed for at least 18 months and median observation time is 21 months. The results will be presented as an online poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. The 60% ORR (6 complete responses (CR); 6 partial responses (PR) from a 20-patient cohort) with 30% CR, clearly exceeds the response rate for pembrolizumab alone in advanced melanoma (33-37% ORR and 5-12% CR)*. The median progression-free survival for the UV1/pembrolizumab combination in the study was 18.9 months compared with 5.5-11.6 months* for pembrolizumab alone in advanced melanoma. The overall survival was 80%, with the median overall survival yet to be reached after 21-months of follow-up. “These very strong and exciting data further strengthen the foundation for our broad Phase II clinical program for UV1,” said Jens Bjørheim, Chief Medical Officer at Ultimovacs. “To show this level of beneficial clinical response while being safe and well-tolerated in combination with pembrolizumab underscores our development strategy to show that UV1 can provide a significant increase in therapeutic effect in a broad range of indications and combinations.” The rationale for the use of UV1 is that patients with advanced malignant melanoma often lack the relevant T cells to obtain durable benefits from the use of pembrolizumab alone. UV1 expands T cells that have the potential to increase the breadth and diversity of the immune response towards all parts of the tumor. The data comes from Ultimovacs’ open-label Phase I study (NCT03538314) and will be shown as a poster presentation at ASCO, to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The data also shows that the UV1/pembrolizumab combination is well tolerated, with adverse events largely restricted to low grade effects, mainly injection site reactions. “These data reinforce our conviction that UV1 can play a transformative role in the treatment of conditions such as malignant melanoma,” said Carlos de Sousa, CEO of Ultimovacs. “It suggests that UV1 in combination with checkpoint inhibitors like pembrolizumab can mobilize the immune system to fight cancer. This is very encouraging for melanoma patients and for those involved with the roll-out of Ultimovacs’ broader programs in solid cancers.” Webcast A corporate webcast will be held on Thursday 20 May 2021, 10:00 CEST. Carlos de Sousa, CEO of Ultimovacs and Jens Bjørheim, CMO, will discuss the ASCO abstract. It will be possible to submit written questions during the presentation. The webcast will be available subsequently on the company website;
OSL:ULTILong
by savepiginvest
On verge of major breakout (continued..)Bullish harmonic. Pattern in combination of low float stock such as KMPH is very bullish setup especially since the stock has been hovering around previous highest volume day of 1M shares traded. the stock has been hovering around 900k and reluctant to break 1M but the tutes are getting anxious as investor Samuel Braun decided to add to his position and steal shares from tutes attempting to manipulate stock price so they could add more. With KMPH’s new big blockbuster treatment for ADHD and main ingredient SDX which was recently announced to have received a Schedule IV narcotic (all other Stimulant based ADHD such as adderrall and Ritalin are schedule 2) the company looks to soon initiate KP879 which is comprised of SDX and will be first of kind treatment for stimulant use disorder (there are currently no treatments for SUD). Also Corium has told KMPH CEO Travis Mickle they would like to see kmph get Azstarys label expansion for treatment of ADHD in pre-schoolers! Exciting times ahead for Kempharm team. Disclosure: i am long KMPH. I am not a licensed financial analyst and this information is to be used for educational purposes only.
KLong
by follow_the_money
AION Formulations Kill Breast Cancer Cells Through Multiple PathBullish MACD cross (technical buy signal) + monster news!! Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways LONDON and TORONTO, May 18, 2021 /PRNewswire/ -- Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's affiliate, Apollon Formularies Jamaica Limited ("Apollon Jamaica"), and the medicinal mushroom formulations were developed by AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a subsidiary of Aion. The testing results showed that Apollon Jamaica's medical cannabis formulations were particularly effective in killing living HER2+ cancer cells directly (direct cytotoxicity), while Aion's medicinal mushroom formulations were most effective in stimulating the immune system's T-cell production to attack and kill HER2+ cancer cells and through macrophage induced phagocytosis. When the two formulations were combined, nearly 100% of HER2+ breast cancer cells in 3D cell cultures were killed through the three different pathways. Stephen D. Barnhill, M.D., CEO of Apollon, commented, "Cannabinoids have been seen to exert 'antitumor' effects by a number of different means, including killing cancer cells directly as well as inhibiting transformed cell growth and tumor metastasis. Apollon Jamaica, using results from its proprietary artificial intelligence based analysis on strain genetics, has cultivated and processed certain of its proprietary medical cannabis products with cancer treatment expressly in mind. We are excited that our formulations have been validated via independent laboratory testing to kill HER2+ breast cancer cells in 3D cell culture through direct cytotoxicity." Dr. Herbert A. Fritsche, Chief Science Officer of Aion and former Professor and Director of Clinical Chemistry at the University of Texas, MD Anderson Cancer Center, stated, "Our recent medicinal mushroom formulation testing demonstrated that two formulations, AION F7 and AION F8, when used together, showed high efficacy in killing HER2+ breast cancer cells via immune stimulated cytotoxicity by T-cells and macrophages. This result suggests that these Aion medicinal mushroom formulations have a similar effectiveness as Trastuzumab (Herceptin, Roche), a monoclonal antibody treatment." Added Dr. Barnhill, "It is our theory that use of a combination of anticancer therapies, especially ones involving separate treatment pathways, may have advantages over single-agent-based strategies as they may allow simultaneous or serial targeting of tumor growth, progression, and/or spreading at different levels with efforts to kill cancer cells. As a part of the independent laboratory testing, we have demonstrated that, when Apollon's medical cannabis formulations are used together with Aion's medicinal mushroom formulations, nearly 100% of HER2+ breast cancer cells in 3D cell culture are killed through multiple different pathways. Pursuant to the Research & Development and the Retail -Therapeutic licences issued to Apollon, we intend to have Jamaican physicians begin treating patients who have HER2+ breast cancer in Jamaica where each company's formulations can be available by physician prescription. This will allow us to corroborate these exciting laboratory results by observing the results of treatment in human patients." Worldwide, breast cancer is the most common cancer in women and accounts for the most cancer related deaths. In 2019, the breast cancer market totalled over US$20 billion, with 68% of therapies sold targeting HER2 or CDK4/6. Market research analysts Paul Wilcock and Rachel M. Webster of Decision Resources Group (part of Clarivate, London, UK) have predicted that the breast cancer market will grow 9% annually and be over US$47 billion by 2029. Commented Mr. Paul Burke, Chairman and CEO of Apollon Jamaica, "These test results and the plan to begin treatments in Jamaica are very exciting developments. Traditional chemotherapy, radiation and surgery cancer treatment protocols are expensive and require a great deal of infrastructure. As a result many women in Jamaica and worldwide have gone without, or with only limited, treatment." The Apollon Jamaica Chairman went on to say, "The combined formulations of Apollon and Aion are expected to be comparatively inexpensive, providing an opportunity for all women to have their breast cancer treated. I look forward to collaborating with Aion with regard to our shared vision to bring these formulations to market as quickly as possible and in a manner that allows all Jamaican women with HER2+ breast cancer, as well as, women traveling from international locations to Jamaica as medical tourists for our treatment, to have access to quality care." The testing occurred as a part of a Joint Testing Agreement between the parties and was authorized in accordance with Apollon Jamaica's Research & Development licence issued by the Jamaican government's Cannabis Licensing Authority (CLA). In the performance of services under the Joint Testing Agreement, each party confined its activities to those permitted by applicable law, with CLA licensed Apollon Jamaica performing medical cannabis activities and AI Pharma performing services involving functional medicinal mushrooms. Mushroom formulations containing psilocybin or psilocin, which comes from psychedelic mushrooms, were not included as a part of the joint testing. AI Pharma currently has an agreement with Apollon Jamaica to license equipment and an agreement with Doc's Place International, Inc. to sublease space in order that AI Pharma can perform cultivation, research and development, processing and treatment services in Jamaica with regard to its medicinal mushrooms formulations. The companies next expect to negotiate a joint license agreement involving their formulations and intellectual property whereby AI Pharma may exclusively use Apollon Jamaica's medical cannabis formulations in their combined product lines in the US and Canada, and Apollon may exclusively use certain of Aion's medicinal (non-psilocybin) mushroom products in their combined product lines in Europe and Jamaica, where legal. This structure would allow Apollon to benefit from Aion's sales in the US and Canada, where Apollon Jamaica is unable to sell medical cannabis under current US and UK law. In both instances, medical care will be done by physicians and psychiatrists authorized to prescribe medications and treat patients.
CSE:AIONLong
by wealth_bakery